On the public citation graph

The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis

https://doi.org/10.21037/apm-21-1564
0 signed · 66 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/archinternmed.2010.198openalex-snapshot
Gout, Allopurinol Use, and Heart Failure Outcomes
inferredcites →https://doi.org/10.1002/art.1780290111openalex-snapshot
The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality
inferredcites →https://doi.org/10.1002/art.22014openalex-snapshot
Gout and the risk of acute myocardial infarction
inferredcites →https://doi.org/10.1002/art.24209openalex-snapshot
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trial
inferredcites →https://doi.org/10.1002/art.30520openalex-snapshot
Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008
inferredcites →https://doi.org/10.1002/art.41266openalex-snapshot
Underscoring the Importance of Allopurinol in Treating Gout: Results of a Food and Drug Administration–Mandated Safety Trial
inferredcites →https://doi.org/10.1002/cpt.1377openalex-snapshot
Hypersensitivity and Cardiovascular Risks Related to Allopurinol and Febuxostat Therapy in Asians: A Population‐Based Cohort Study and Meta‐Analysis
inferredcites →https://doi.org/10.1007/s00296-013-2857-2openalex-snapshot
As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout
inferredcites →https://doi.org/10.1007/s10067-011-1699-0openalex-snapshot
Prevalence of hyperuricemia in Bangkok population
inferredcites →https://doi.org/10.1007/s40265-019-01081-5openalex-snapshot
Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy
inferredcites →https://doi.org/10.1007/s40266-014-0214-0openalex-snapshot
Urate-Lowering Therapy: Current Options and Future Prospects for Elderly Patients with Gout
inferredcites →https://doi.org/10.1016/0002-9343(84)90743-5openalex-snapshot
Severe allopurinol toxicity
inferredcites →https://doi.org/10.1016/j.amjmed.2015.01.013openalex-snapshot
Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: A Cohort Study
inferredcites →https://doi.org/10.1016/j.ijcard.2017.10.045openalex-snapshot
Serum uric acid levels are associated with cardiovascular risk score: A post hoc analysis of the EURIKA study
inferredcites →https://doi.org/10.1016/j.jacc.2010.12.052openalex-snapshot
Mechanistic Insights Into the Therapeutic Use of High-Dose Allopurinol in Angina Pectoris
inferredcites →https://doi.org/10.1016/j.jjcc.2014.12.017openalex-snapshot
Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD)
inferredcites →https://doi.org/10.1016/j.mayocp.2019.03.001openalex-snapshot
Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study
inferredcites →https://doi.org/10.1016/j.numecd.2019.06.016openalex-snapshot
The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia – A systematic review and meta-analysis
inferredcites →https://doi.org/10.1016/j.semarthrit.2013.05.004openalex-snapshot
A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout
inferredcites →https://doi.org/10.1016/s0022-5347(17)50916-7openalex-snapshot
Severe Allopurinol Toxicity. Description and Guidelines for Prevention in Patients With Renal Insufficiency
inferredcites →https://doi.org/10.1016/s0190-9622(79)70031-4openalex-snapshot
The allopurinol hypersensitivity syndrome
inferredcites →https://doi.org/10.1056/nejmoa050373openalex-snapshot
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout
inferredcites →https://doi.org/10.1056/nejmoa1710895openalex-snapshot
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
inferredcites →https://doi.org/10.1073/pnas.0409500102openalex-snapshot
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
inferredcites →https://doi.org/10.1093/rheumatology/kem056aopenalex-snapshot
British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout
inferredcites →https://doi.org/10.1093/rheumatology/kex065openalex-snapshot
Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis
inferredcites →https://doi.org/10.1093/rheumatology/kez189openalex-snapshot
Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study
inferredcites →https://doi.org/10.1093/rheumatology/kez576openalex-snapshot
Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users
inferredcites →https://doi.org/10.1097/crd.0b013e318229a908openalex-snapshot
Allopurinol as a Cardiovascular Drug
inferredcites →https://doi.org/10.1097/hjh.0000000000000701openalex-snapshot
Serum uric acid and the risk of cardiovascular and renal disease
inferredcites →https://doi.org/10.1111/1756-185x.12648openalex-snapshot
A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia
inferredcites →https://doi.org/10.1111/j.1365-2125.2010.03887.xopenalex-snapshot
Impact of allopurinol use on urate concentration and cardiovascular outcome
inferredcites →https://doi.org/10.1136/ard.2009.122770openalex-snapshot
Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study
inferredcites →https://doi.org/10.1155/2015/762820openalex-snapshot
Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis
inferredcites →https://doi.org/10.1186/1471-2318-12-11openalex-snapshot
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
inferredcites →https://doi.org/10.1186/ar2978openalex-snapshot
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
inferredcites →https://doi.org/10.1371/journal.pone.0099102openalex-snapshot
Allopurinol Therapy in Gout Patients Does Not Associate with Beneficial Cardiovascular Outcomes: A Population-Based Matched-Cohort Study
inferredcites →https://doi.org/10.21037/apm-21-1564openalex-snapshot
The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis
inferredcites →https://doi.org/10.3109/03009742.2015.1099729openalex-snapshot
Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study
inferredcites →https://doi.org/10.3899/jrheum.080814openalex-snapshot
Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout
inferredcites →https://doi.org/10.3899/jrheum.140457openalex-snapshot
Cardiovascular Risk Factors and Comorbidities in Patients with Hyperuricemia and/or Gout: A Systematic Review of the Literature

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4882085openalex-extracted
inferred← citeshttps://doi.org/10.1007/s40266-024-01098-wopenalex-snapshot
The Effects of Pharmacological Urate-Lowering Therapy on Cardiovascular Disease in Older Adults with Gout
inferred← citeshttps://doi.org/10.1016/j.amjmed.2024.09.018openalex-snapshot
Febuxostat Leads to Better Cardiovascular Outcomes Compared to Allopurinol in Patients With Advanced Chronic Kidney Disease: A Population-Based Cohort Study
inferred← citeshttps://doi.org/10.1016/j.bbadis.2024.167051openalex-snapshot
Discovery of 2,8-dihydroxyadenine in HUA patients with uroliths and biomarkers for its associated nephropathy
inferred← citeshttps://doi.org/10.1038/s41598-024-79350-xopenalex-snapshot
Phyllanthi Fructus ameliorates hyperuricemia and kidney injure via inhibiting uric acid synthesis, modulating urate transporters, and alleviating inflammation
inferred← citeshttps://doi.org/10.1080/14740338.2024.2430304openalex-snapshot
Cardiovascular outcomes of urate-lowering therapies in patients with gout or hyperuricemia: a network meta-analysis
inferred← citeshttps://doi.org/10.1096/fj.202300393ropenalex-snapshot
Hyperuricemia: A key contributor to endothelial dysfunction in cardiovascular diseases
inferred← citeshttps://doi.org/10.1111/1756-185x.14558openalex-snapshot
Effect of febuxostat on adverse events and mortality in gout in Taiwan: An interrupted time series analysis
inferred← citeshttps://doi.org/10.1186/s40360-023-00723-5openalex-snapshot
Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.12659/msm.944314openalex-snapshot
Comparative Cardiovascular Risks of Febuxostat and Allopurinol in Patients with Diabetes Mellitus and Chronic Kidney Disease
inferred← citeshttps://doi.org/10.12677/acm.2025.15103011openalex-snapshot
Exploring the Mechanism of Treatment of Gouty Arthritis from “Chronic Diseases Transforming to Collaterals”
inferred← citeshttps://doi.org/10.18549/pharmpract.2026.1.3416openalex-snapshot
Possible Effect of Allopurinol and Risk of Dementia: An Updated Meta-Analysis
inferred← citeshttps://doi.org/10.21037/apm-22-618openalex-snapshot
Is febuxostat associated with higher risk of cardiovascular death than allopurinol in treating gout or asymptomatic hyperuricemia?
inferred← citeshttps://doi.org/10.31083/bjhm52969openalex-snapshot
Influencing Factors and a Predictive Model for Cardiovascular Events in Patients With Hyperuricemia Treated With Febuxostat
inferred← citeshttps://doi.org/10.3390/jcdd10090379openalex-snapshot
Allopurinol for Secondary Prevention in Patients with Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.3390/jcm15145479openalex-snapshot
Serum Uric Acid and Mortality Risk in Chronic Kidney Disease: A Dose–Response Analysis
inferred← citeshttps://doi.org/10.47487/apcyccv.v3i4.240openalex-snapshot
Riesgo cardiovascular en pacientes con crisis gotosa: ¿existe alguna asociación y necesidad de tratamiento?
inferred← citeshttps://doi.org/10.5114/aic.2023.129213openalex-snapshot
The relation between uric acid level and blood pressure values among patients hospitalized in a department of internal medicine
inferred← citeshttps://doi.org/10.51847/i15koshyqoopenalex-snapshot
Cardiovascular Safety of Febuxostat versus Allopurinol in Complex Patient Populations
inferred← citeshttps://doi.org/10.52312/jdrs.2025.1976openalex-snapshot
The efficacy and safety of different doses of febuxostat and allopurinol: A meta-analysis
inferred← citeshttps://doi.org/10.55164/ajstr.v27i1.250948openalex-snapshot
Molecular Docking of Bioactive Compounds from Thai Medicinal Plants Against Xanthine Oxidase for Gout Treatment
inferred← citeshttps://doi.org/10.5603/rf.2022.0007openalex-snapshot
Cardiological and rheumatological expert statement on the management of asymptomatic hyperuricemia in patients at high cardiovascular risk
inferred← citeshttps://doi.org/10.6084/m9.figshare.26654248openalex-snapshot
Additional file 1 of Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.6084/m9.figshare.26654251openalex-snapshot
Additional file 2 of Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials
showing the first 24 of 25
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.